Biopharmaceutical Company-Zydus launches biosimilar Aflibercept 2 mg ANYRA for advancing ophthalmic care

Zydus Lifesciences has launched Anyra™, marking a significant milestone as India’s first indigenously developed biosimilar of Aflibercept 2 mg. This therapeutic biologic is designed to treat several vision-threatening conditions, including neovascular (wet) Age-related Macular Degeneration, Diabetic Retinopathy, and various forms of macular edema. By introducing this high-quality, affordable alternative, Zydus aims to expand patient access to critical anti-VEGF therapies. The launch is supported by an agreement with Regeneron Pharmaceuticals and Bayer, reinforcing the company's commitment to advancing ophthalmic care through its extensive domestic manufacturing and research capabilities.

The introduction of Anyra™ addresses a pressing healthcare challenge in India, where over 100 million people live with diabetes and millions more suffer from retinal diseases. Given that chronic retinal conditions often require repeated, long-term injections, the availability of a locally produced biosimilar helps alleviate the financial burden on patients and improves treatment adherence. Dr Sharvil P. Patel, Managing Director of Zydus Lifesciences, emphasised that this transformative step leverages the company's robust biosimilar portfolio to reduce preventable blindness. By providing a cost-effective treatment option, Zydus seeks to lower the long-term disease burden for the millions of Indian patients at risk of irreversible vision loss.

About Zydus Lifesciences Limited

Zydus Lifesciences Limited is an innovation-led life-sciences company with leadership positions across pharmaceuticals and consumer wellness, supported by an emerging MedTech franchise and a global footprint across the United States, India and other international markets. As of September 30, 2025, the group employs 29,000 people worldwide, including 1,500 scientists engaged in R&D, and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries.

Disclaimer: The article is for informational purposes only and not investment advice.